An investigation on behalf of investors in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares over potential wrongdoing at Spectrum Pharmaceuticals was announced and NASDAQ:SPPI stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (SBWire) -- 04/15/2015 --An investigation on behalf of current long-term investors in shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares was announced over potential breaches of fiduciary duties by certain officers and directors at Spectrum Pharmaceuticals.

Investors who purchased shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Spectrum Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

On March 12, 2013, Spectrum Pharmaceuticals, Inc. commented on anticipated first quarter performance and updated its 2013 outlook for the Company. Spectrum Pharmaceuticals, Inc. said that based upon recent communications with customers it anticipates a change in ordering patterns of FUSILEV® following the recent stabilization of the folate analog market. Spectrum Pharmaceuticals, Inc. said it expects that FUSILEV sales will be approximately $10 to $15 million for the first quarter of the year, and approximately $80 to $90 million for the 2013 fiscal year. Furthermore, Spectrum Pharmaceuticals, Inc. said that it anticipates total company revenues in the range of $160 to $180 million for the full-year 2013.

On March 14, 2014, a lawsuit was filed against Spectrum Pharmaceuticals, Inc over alleged securities laws violations. The plaintiff claimed that between August 8, 2012 and March 12, 2013 defendants allegedly continually dismissed concerns that sales of FUSILEV would be adversely affected by increased supplies of leucovorin and allegedly concealed the impact that the increased availability of leucovorin would have on FUSILEV sales and as a result of defendants' statements, Spectrum Pharmaceuticals Inc's stock traded at artificially inflated prices between August 8, 2012 and March 12, 2013, reaching a high of $13.05 per share on September 18, 2012.

Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) declined from $12.72 per share in early 2013 to as low as $6.92 per share on March 21, 2013.

Those who purchased shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com